Troy Asset Management Ltd Has $20.51 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Troy Asset Management Ltd cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 24.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,813 shares of the company's stock after selling 46,285 shares during the period. Johnson & Johnson comprises about 0.7% of Troy Asset Management Ltd's holdings, making the stock its 28th largest position. Troy Asset Management Ltd's holdings in Johnson & Johnson were worth $20,509,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. MRP Capital Investments LLC lifted its stake in Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co raised its holdings in shares of Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after buying an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management boosted its stake in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock valued at $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after acquiring an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC raised its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after acquiring an additional 67 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Johnson & Johnson Trading Up 1.5 %

Shares of NYSE:JNJ traded up $2.47 during midday trading on Monday, hitting $166.18. The company had a trading volume of 5,793,396 shares, compared to its average volume of 9,037,503. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a fifty day simple moving average of $158.68 and a 200 day simple moving average of $156.07. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $400.48 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business posted $2.29 earnings per share. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Finally, Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $171.33.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.